Chief Corporate Affairs and Communications Officer · Vanda Pharmaceuticals Inc. (VNDA)

Aranthan Jones

FY2020 is the first fiscal year CompBrief holds for Aranthan Jones as a named executive officer of Vanda Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,378,317

Salary $406,104Stock awards $339,600

4th of 7 named executive officers at Vanda Pharmaceuticals by FY2020 total.

7 named officers on file for Vanda Pharmaceuticals, FY2020

Aranthan Jones’s pay file — $29

  • 1 fiscal year of pay, line by line
  • VNDA’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vanda Pharmaceuticals’s whole pay program stands against its peers

  • Vanda Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VNDA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2021 (DEF 14A).

Free

Get Aranthan Jones’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Aranthan Jones compensation by year

Vanda Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Vanda Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$406,104
Bonus$0
Stock awards$339,600
Option awards$397,915
Non-equity incentive$201,021
Pension and deferred compensation$0
All other$33,677
Total$1,378,317

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vanda Pharmaceuticals Inc. DEF 14A filed April 22, 2021, accession 0001347178-21-000008, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vanda Pharmaceuticals Inc. filed document, accession 0001347178-21-000008. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU45,000$591,300—
RSU30,000$394,200—
Option38,751—$12.27
Option70,000—$11.32

Per the Outstanding Equity Awards at Fiscal Year-End table in Vanda Pharmaceuticals Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Vanda Pharmaceuticals’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Mihael PolymeropoulosPresident and Chief Executive Officer$2,913,420
Joakim WijkstromSenior Vice President, Chief Marketing Officer$1,523,885
Timothy WilliamsSenior Vice President, General Counsel and Secretary$1,379,061
Aranthan Jones · this pageChief Corporate Affairs and Communications Officer$1,378,317
Gunther BirznieksSenior Vice President, Business Development$1,377,808
Kevin MoranSenior Vice President, Chief Financial Officer and Treasurer$1,319,699
James KellyFormer Executive Vice President, Chief Financial Officer and Treasurer$140,274

The full Vanda Pharmaceuticals compensation record

free company brief

This page is one person within Vanda Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vanda Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vanda Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Aranthan Jones's compensation dossier · One-time report. No refunds.